Accesso libero

Experience of switching to NovoEight: views of people with haemophilia

Debra Pollard
Debra Pollard
, 
Kate Khair
Kate Khair
 e 
Mike Holland
Mike Holland
   | 17 giu 2020
The Journal of Haemophilia Practice's Cover Image
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Cita
Article Category: Clinical Practice
Pubblicato online: 17 giu 2020
Pagine: 70 - 77
DOI: https://doi.org/10.17225/jhp00157
Parole chiave
© 2020 Debra Pollard et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

A survey of people with haemophilia in the UK whose factor product was switched to NovoEight found that although most felt they had little influence on the decision to switch, the majority continued to have confidence in the new treatment© Shutterstock
A survey of people with haemophilia in the UK whose factor product was switched to NovoEight found that although most felt they had little influence on the decision to switch, the majority continued to have confidence in the new treatment© Shutterstock

Figure 1

Participants’ perceived level of influence over the decision to switch product
Participants’ perceived level of influence over the decision to switch product

Figure 2

The proportion of patients who had to mix more than one vial of product before and after switching
The proportion of patients who had to mix more than one vial of product before and after switching

Figure 3

Participants’ views on packaging, user kits and ease of infusion compared with previous product
Participants’ views on packaging, user kits and ease of infusion compared with previous product

Figure 4

Participants’ rating views on NovoEight
Participants’ rating views on NovoEight

Comments on NovoEight offered by participants

POSITIVE COMMENTSNEUTRAL COMMENTSNEGATIVE COMMENTS
Packagingn=11Smaller boxes, ease of storingn=9n=13Two boxes, takes space
Ease of mixingn=8Easier to mix and administer
User kitsn=6Smaller, fewer resources wastedn=3Ordering ancillaries separately is inconvenient
Product overalln=3No bleeds, less painn=3Concerns about half-life

Statistical analyses based on those switching from ReFacto compared with other products (n=73/77)

Preparation timeShorterUnchangedGreaterP-value
ReFacto133460.0068
Non-ReFacto1270
Number of vialsFewerUnchangedMore
Refacto74510.055
Non-ReFacto7110
Trough levelsLowerUnchangedHigherNot tested/unknownP-value
ReFacto1267170.92
Non-ReFacto0937
ConfidenceBetterSameWorse
ReFacto64430.11
Non-ReFacto6122
Satisfaction rating12345
ReFacto121514210.020
Non-ReFacto002413
Packaging rating12345
ReFacto95179130.0073
Non-ReFacto015211

Patient characteristics

ALL PARTICIPANTS(N=77)ADULTS AGED 16+ YEARS(N=63)CAREGIVERS OF CHILDREN AGED <16 YEARS(N=14)
SeveritySevere (n=74)Moderate (n=1)Mild (n=2)Severe (n=60)Moderate (n=1)Mild (n=2)Severe (n=14)Moderate (n=0)Mild (n=0)
TreatmentOn demand (n=4)Prophylaxis (n=73)On demand (n=4)Prophylaxis (n=59)On demand (n=0)Prophylaxis (n=14)
Mean age at switch31.57 years11.14 years
Time on previous medication7.28 years7.28 years
Previous FVIII productReFacto (n=53)Helixate (n=10)Kogenate (n=5)Fanhdi (n=4)Optivate (n=1)unknown (n=4)ReFacto (n=43)Helixate (n=10)Kogenate (n=4)Fanhdi (n=4)Optivate (n=0)unknown (n=2)ReFacto (n=10)Helixate (n=0)Kogenate (n=1)Fanhdi (n=0)Optivate (n=1)unknown (n=2)
eISSN:
2055-3390
Lingua:
Inglese
Frequenza di pubblicazione:
Volume Open
Argomenti della rivista:
Medicine, Basic Medical Science, other, Clinical Medicine, Pharmacy, Pharmacology
Feed RSS della rivista